Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

Maria Gabriella Ferrandina, Giovanni Scambia, Manuela Ludovisi, D Lorusso, S Pignata, R Viganò, S Scalone, P Scollo, E Breda, A Pietragalla

Risultato della ricerca: Contributo in rivistaArticolo in rivista

33 Citazioni (Scopus)

Fingerprint

Entra nei temi di ricerca di 'Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group'. Insieme formano una fingerprint unica.

Medicine & Life Sciences